DOAC Reversal Agents
Gyen Musgrave 
Abstract
Direct oral anticoagulant (DOAC) drugs revolutionized the anticoagulant market and pose an attractive alternative approach to the treatment and prevention of VTE, as well as the prevention of stroke in atrial fibrillation (A. Fib) patients. DOAC agents include dabigatran etexilate (PRADAXA), rivaroxaban (XARELTO), apixaban (ELIQUIS), and edoxaban (SAVAYSA). Dabigatran etexilate functions mechanistically as a direct thrombin inhibitor, whereas rivaroxaban, apixaban, and edoxaban are factor Xa inhibitors. These agents are more expensive when compared to warfarin therapy (classic Vitamin K antagonist), but have fewer monitoring demands, fewer food interactions, and may offer a more patient-friendly outpatient dosing regimen.1 One unique characteristic of DOACs is the ability for DOAC anticoagulation effects to be rapidly reversed. DOAC specific reversal agents (idarucizumab, andexanet alfa, and ciraparantag) have recently become available or are currently undergoing phase 2 and 3 trials. This review article will focus on specific reversal agents and some of their characteristics.
Full Text
Vol1Article5.pdf
File Size: 433 kb
File Type: pdf
Download File

Notice and Disclaimer

Medicine is an ever-changing science.  As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required.  The authors and the publisher of this work have checked with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the time of publication.  However, in view of the possibility of human error or changes in medical sciences, neither the authors nor the publisher nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is accurate or complete, and they disclaim all responsibility for any errors or omissions or for the results obtained from use of the information contained in this work.    Readers are encouraged to confirm the information contained herein with other sources.   For example and in particular, readers are advised to check the product information sheet included in the package of each drug they plan to administer to be certain that the information contained in this work is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.

Subscribe to ARxCH